{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:59Z","timestamp":1786979939360,"version":"build-2736575974"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00277-025-06499-4","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T03:27:58Z","timestamp":1753846078000},"page":"3943-3962","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic significance of in patients with chronic lymphocytic leukemia: A meta-analysis"],"prefix":"10.1007","volume":"104","author":[{"given":"Liping","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"issue":"3","key":"6499_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/ajh.27546","volume":"100","author":"M Hallek","year":"2025","unstructured":"Hallek M (2025) Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy. Am J Hematol 100(3):450\u2013480. https:\/\/doi.org\/10.1002\/ajh.27546","journal-title":"Am J Hematol"},{"key":"6499_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae082","author":"The Surveillance E, Results E (SEER) Program of the National Cancer Institute","year":"2024","unstructured":"The Surveillance E, Results E (SEER) Program of the National Cancer Institute (2024) Cancer stat facts: leukemia\u2014Chronic lymphocytic leukemia (CLL). J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djae082","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"6499_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/joim.12455","volume":"279","author":"P Baliakas","year":"2016","unstructured":"Baliakas P, Mattsson M, Stamatopoulos K, Rosenquist R (2016) Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed? J Intern Med 279(4):347\u2013357. https:\/\/doi.org\/10.1111\/joim.12455","journal-title":"J Intern Med"},{"issue":"3","key":"6499_CR4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/ajh.24282","volume":"91","author":"KR Rai","year":"2016","unstructured":"Rai KR, Jain P (2016) Chronic lymphocytic leukemia (CLL)-Then and now. Am J Hematol 91(3):330\u2013340. https:\/\/doi.org\/10.1002\/ajh.24282","journal-title":"Am J Hematol"},{"issue":"10129","key":"6499_CR5","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/s0140-6736(18)30422-7","volume":"391","author":"M Hallek","year":"2018","unstructured":"Hallek M, Shanafelt TD, Eichhorst B (2018) Chronic lymphocytic leukaemia. Lancet (London England) 391(10129):1524\u20131537. https:\/\/doi.org\/10.1016\/s0140-6736(18)30422-7","journal-title":"Lancet (London England)"},{"key":"6499_CR6","doi-asserted-by":"publisher","unstructured":"Maher N, Mouhssine S, Matti BF, Alwan AF, Gaidano G (2023) Treatment refractoriness in chronic lymphocytic leukemia: old and new molecular biomarkers. Int J Mol Sci 24(12). https:\/\/doi.org\/10.3390\/ijms241210374","DOI":"10.3390\/ijms241210374"},{"issue":"3","key":"6499_CR7","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/leu.2017.296","volume":"32","author":"D Benedetti","year":"2018","unstructured":"Benedetti D, Tissino E, Pozzo F, Bittolo T, Caldana C, Perini C, Martorelli D, Bravin V, D\u2019Agaro T, Rossi FM, Bomben R, Santinelli E, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Poeta G, Rossi D, Gaidano G, Dal Bo M, Gattei V, Zucchetto A (2018) NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-kappaB pathways. Leukemia 32(3):654\u2013662. https:\/\/doi.org\/10.1038\/leu.2017.296","journal-title":"Leukemia"},{"key":"6499_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40364-020-00222-3","volume":"8","author":"X Yun","year":"2020","unstructured":"Yun X, Zhang Y, Wang X (2020) Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia. Biomark Res 8:40. https:\/\/doi.org\/10.1186\/s40364-020-00222-3","journal-title":"Biomark Res"},{"issue":"7","key":"6499_CR9","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1001\/jamaoncol.2015.0779","volume":"1","author":"C Nabhan","year":"2015","unstructured":"Nabhan C, Raca G, Wang YL (2015) Predicting prognosis in chronic lymphocytic leukemia in the contemporary era. JAMA Oncol 1(7):965\u2013974. https:\/\/doi.org\/10.1001\/jamaoncol.2015.0779","journal-title":"JAMA Oncol"},{"issue":"5","key":"6499_CR10","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/leu.2014.318","volume":"29","author":"GD Te Raa","year":"2015","unstructured":"Te Raa GD, Derks IA, Navrkalova V, Skowronska A, Moerland PD, van Laar J, Oldreive C, Monsuur H, Trbusek M, Malcikova J, Lod\u00e9n M, Geisler CH, H\u00fcllein J, Jethwa A, Zenz T, Pospisilova S, Stankovic T, van Oers MH, Kater AP, Eldering E (2015) The impact of SF3B1 mutations in CLL on the DNA-damage response. Leukemia 29(5):1133\u20131142. https:\/\/doi.org\/10.1038\/leu.2014.318","journal-title":"Leukemia"},{"issue":"3","key":"6499_CR11","doi-asserted-by":"publisher","first-page":"e1757","DOI":"10.1002\/cnr2.1757","volume":"6","author":"R Sadria","year":"2023","unstructured":"Sadria R, Motamed N, Saberi Anvar M, Mehrabani Yeganeh H, Poopak B (2023) Prognostic correlation of NOTCH1 and SF3B1 mutations with chromosomal abnormalities in chronic lymphocytic leukemia patients. Cancer Rep (Hoboken) 6(3):e1757. https:\/\/doi.org\/10.1002\/cnr2.1757","journal-title":"Cancer Rep (Hoboken)"},{"issue":"41","key":"6499_CR12","doi-asserted-by":"publisher","first-page":"69916","DOI":"10.18632\/oncotarget.19455","volume":"8","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Chen S, Chen S, Chen G, Zhang R, Li J, Qu J (2017) SF3B1 mutation is a prognostic factor in chronic lymphocytic leukemia: a meta-analysis. Oncotarget 8(41):69916\u201369923. https:\/\/doi.org\/10.18632\/oncotarget.19455","journal-title":"Oncotarget"},{"key":"6499_CR13","doi-asserted-by":"publisher","unstructured":"Abramenko I, Bilous N, Chumak A, Kryachok I, Fedorenko Z, Martina Z, Dyagil I (2021) The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients. Leuk Res 110. https:\/\/doi.org\/10.1016\/j.leukres.2021.106686","DOI":"10.1016\/j.leukres.2021.106686"},{"issue":"8","key":"6499_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.21037\/atm.2019.03.63","volume":"7","author":"Y Miao","year":"2019","unstructured":"Miao Y, Zou YX, Gu DL, Zhu HC, Zhu HY, Wang L, Liang JH, Xia Y, Wu JZ, Shao CL, Fan L, Zhang Z, Xu W, Li JY (2019) SF3B1 mutation predicts unfavorable treatment-free survival in Chinese chronic lymphocytic leukemia patients. Annals Translational Med 7(8):176. https:\/\/doi.org\/10.21037\/atm.2019.03.63","journal-title":"Annals Translational Med"},{"issue":"9","key":"6499_CR15","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.3324\/haematol.2020.251488","volume":"106","author":"G Del Poeta","year":"2021","unstructured":"Del Poeta G, Biagi A, Laurenti L, Chiarenza A, Pozzo F, Innocenti I, Postorino M, Rossi FM, Del Principe MI, Bomben R, de Fabritiis P, Bruno A, Cantonetti M, Di Raimondo F, Zucchetto A, Gattei V (2021) Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. Haematologica 106(9):2345\u20132353. https:\/\/doi.org\/10.3324\/haematol.2020.251488","journal-title":"Haematologica"},{"issue":"3","key":"6499_CR16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00277-023-05554-2","volume":"103","author":"CY Shang","year":"2024","unstructured":"Shang CY, Bei LY, Wu JZ, Sheng HR, Yin H, Liang JH, Wang L, Li JY, Li Y, Xu W (2024) NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia. Ann Hematol 103(3):833\u2013841. https:\/\/doi.org\/10.1007\/s00277-023-05554-2","journal-title":"Ann Hematol"},{"issue":"6","key":"6499_CR17","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1080\/10428194.2021.2020779","volume":"63","author":"JA Burger","year":"2022","unstructured":"Burger JA, Robak T, Demirkan F, Bairey O, Moreno C, Simpson D, Munir T, Stevens DA, Dai S, Cheung LWK, Kwei K, Lal I, Hsu E, Kipps TJ, Tedeschi A (2022) Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma 63(6):1375\u20131386. https:\/\/doi.org\/10.1080\/10428194.2021.2020779","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"6499_CR18","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med 18(3):e1003583. https:\/\/doi.org\/10.1371\/journal.pmed.1003583","journal-title":"PLoS Med"},{"issue":"15","key":"6499_CR19","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008\u20132012. https:\/\/doi.org\/10.1001\/jama.283.15.2008","journal-title":"JAMA"},{"issue":"9","key":"6499_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"6499_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177\u2013188. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"issue":"4","key":"6499_CR22","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088\u20131101","journal-title":"Biometrics"},{"issue":"7109","key":"6499_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Res ed) 315(7109):629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ (Clinical Res ed)"},{"key":"6499_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/blood-2011-08-373159","volume":"118","author":"D Rossi","year":"2011","unstructured":"Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M, Fangazio M, Vaisitti T, Guarini A, Giudice ID, Cerri M, Cresta S, Deambrogi C, Gargiulo E, Gattei V, Forconi F, Bertoni F, Deaglio S, Rabadan R, Pasqualucci L, Fo\u00e0 R, Dalla-Favera R, Gaidano G (2011) Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 118:21","journal-title":"Blood"},{"issue":"26","key":"6499_CR25","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","volume":"365","author":"L Wang","year":"2011","unstructured":"Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, Werner L, Sivachenko A, DeLuca DS, Zhang L, Zhang W, Vartanov AR, Fernandes SM, Goldstein NR, Folco EG, Cibulskis K, Tesar B, Sievers QL, Shefler E, Gabriel S, Hacohen N, Reed R, Meyerson M, Golub TR, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ (2011) SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 365(26):2497\u20132506. https:\/\/doi.org\/10.1056\/NEJMoa1109016","journal-title":"N Engl J Med"},{"issue":"3","key":"6499_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3324\/haematol.2011.060129","volume":"97","author":"I Del Giudice","year":"2012","unstructured":"Del Giudice I, Rossi D, Chiaretti S, Marinelli M, Tavolaro S, Gabrielli S, Laurenti L, Marasca R, Rasi S, Fangazio M, Guarini A, Gaidano G, Foa R (2012) NOTCH1mutations in +\u200912 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +\u200912 CLL. Haematologica-the Hematol J 97(3):437\u2013441. https:\/\/doi.org\/10.3324\/haematol.2011.060129","journal-title":"Haematologica-the Hematol J"},{"issue":"3","key":"6499_CR27","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1182\/blood-2012-05-429282","volume":"121","author":"DG Oscier","year":"2013","unstructured":"Oscier DG, Rose-Zerilli MJ, Winkelmann N, Gonzalez de Castro D, Gomez B, Forster J, Parker H, Parker A, Gardiner A, Collins A, Else M, Cross NC, Catovsky D, Strefford JC (2013) The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 121(3):468\u2013475. https:\/\/doi.org\/10.1182\/blood-2012-05-429282","journal-title":"Blood"},{"issue":"7","key":"6499_CR28","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1182\/blood-2013-03-488197","volume":"122","author":"A Schnaiter","year":"2013","unstructured":"Schnaiter A, Paschka P, Rossi M, Zenz T, B\u00fchler A, Winkler D, Cazzola M, D\u00f6hner K, Edelmann J, Mertens D, Kless S, Mack S, Busch R, Hallek M, D\u00f6hner H, Stilgenbauer S (2013) NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood 122(7):1266\u20131270. https:\/\/doi.org\/10.1182\/blood-2013-03-488197","journal-title":"Blood"},{"issue":"5","key":"6499_CR29","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/leu.2012.357","volume":"27","author":"N Villamor","year":"2013","unstructured":"Villamor N, Conde L, Mart\u00ednez-Trillos A, Cazorla M, Navarro A, Be\u00e0 S, L\u00f3pez C, Colomer D, Pinyol M, Aymerich M, Rozman M, Abrisqueta P, Baumann T, Delgado J, Gin\u00e9 E, Gonz\u00e1lez-D\u00edaz M, Hern\u00e1ndez JM, Colado E, Payer AR, Rayon C, Navarro B, Jos\u00e9Terol M, Bosch F, Quesada V, Puente XS, L\u00f3pez-Ot\u00edn C, Jares P, Pereira A, Campo E, L\u00f3pez-Guillermo A (2013) NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 27(5):1100\u20131106. https:\/\/doi.org\/10.1038\/leu.2012.357","journal-title":"Leukemia"},{"key":"6499_CR30","doi-asserted-by":"publisher","unstructured":"Willander K, Dutta RK, Ungerb\u00e4ck J, Gunnarsson R, Juliusson G, Fredrikson M, Linderholm M, S\u00f6derkvist P (2013) NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients. BMC Cancer 13. https:\/\/doi.org\/10.1186\/1471-2407-13-274","DOI":"10.1186\/1471-2407-13-274"},{"issue":"10","key":"6499_CR31","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00277-014-2117-x","volume":"93","author":"MD Bo","year":"2014","unstructured":"Bo MD, Del Principe MI, Pozzo F, Ragusa D, Bulian P, Rossi D, Capelli G, Rossi FM, Niscola P, Buccisano F, Bomben R, Zucchetto A, Maurillo L, de Fabritiis P, Amadori S, Gaidano G, Gattei V, Del Poeta G (2014) NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. Ann Hematol 93(10):1765\u20131774. https:\/\/doi.org\/10.1007\/s00277-014-2117-x","journal-title":"Ann Hematol"},{"issue":"1","key":"6499_CR32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/leu.2013.263","volume":"28","author":"S Jeromin","year":"2014","unstructured":"Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V, Alpermann T, Roller A, Kohlmann A, Haferlach T, Kern W, Schnittger S (2014) SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 28(1):108\u2013117. https:\/\/doi.org\/10.1038\/leu.2013.263","journal-title":"Leukemia"},{"issue":"5","key":"6499_CR33","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/hon.2058","volume":"99","author":"R Santacruz","year":"2014","unstructured":"Santacruz R, Villamor N, Aymerich M, Mart\u00ednez-Trillos A, L\u00f3pez C, Navarro A, Rozman M, Be\u00e0 S, Royo C, Cazorla M, Colomer D, Gin\u00e9 E, Pinyol M, Puente XS, L\u00f3pez-Ot\u00edn C, Campo E, L\u00f3pez-Guillermo A, Delgado J (2014) The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukaemia requiring first-line therapy. Hematol Oncol 99(5):873\u2013880. https:\/\/doi.org\/10.1002\/hon.2058","journal-title":"Hematol Oncol"},{"issue":"21","key":"6499_CR34","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","volume":"123","author":"S Stilgenbauer","year":"2014","unstructured":"Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Doehner K, Buehler A, Boettcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jaeger U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Doehner H (2014) Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 123(21):3247\u20133254. https:\/\/doi.org\/10.1182\/blood-2014-01-546150","journal-title":"Blood"},{"issue":"2","key":"6499_CR35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/leu.2014.196","volume":"29","author":"P Baliakas","year":"2015","unstructured":"Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, Larrayoz M, Kminkova J, Agathangelidis A, Davis Z, Tausch E, Stalika E, Kantorova B, Mansouri L, Scarf\u00f2 L, Cortese D, Navrkalova V, Rose-Zerilli MJ, Smedby KE, Juliusson G, Anagnostopoulos A, Makris AM, Navarro A, Delgado J, Oscier D, Belessi C, Stilgenbauer S, Ghia P, Pospisilova S, Gaidano G, Campo E, Strefford JC, Stamatopoulos K, Rosenquist R (2015) Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 29(2):329\u2013336. https:\/\/doi.org\/10.1038\/leu.2014.196","journal-title":"Leukemia"},{"key":"6499_CR36","doi-asserted-by":"publisher","unstructured":"Hurtado AM, Chen-Liang TH, Przychodzen B, Hamedi C, Munoz-Ballester J, Dienes B, Garcia-Malo MD, Anton AI, de Arriba F, Teruel-Montoya R, Ortuno FJ, Vicente V, Maciejewski JP, Jerez A (2015) Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia. Blood Cancer J 5. https:\/\/doi.org\/10.1038\/bcj.2015.65","DOI":"10.1038\/bcj.2015.65"},{"issue":"7","key":"6499_CR37","doi-asserted-by":"publisher","first-page":"S426","DOI":"10.18632\/oncotarget.3101","volume":"6","author":"Y Xia","year":"2015","unstructured":"Xia Y, Fan L, Wang L, Gale RP, Wang M, Tian T, Wu W, Yu L, Chen YY, Xu W, Li JY (2015) Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans. Oncotarget 6(7):S426\u2013434","journal-title":"Oncotarget"},{"issue":"2","key":"6499_CR38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12185-015-1912-z","volume":"103","author":"T Mitsui","year":"2016","unstructured":"Mitsui T, Koiso H, Nakahashi H, Saitoh A, Shimizu H, Ishizaki T, Ogawa Y, Takizawa M, Yokohama A, Saitoh T, Jinbo T, Ogura H, Handa H, Sawamura M, Sakura T, Karasawa M, Murakami H, Nojima Y, Tsukamoto N (2016) SF3B1 and IGHV gene mutation status predict poor prognosis in Japanese CLL patients. Int J Hematol 103(2):219\u2013226. https:\/\/doi.org\/10.1007\/s12185-015-1912-z","journal-title":"Int J Hematol"},{"issue":"17","key":"6499_CR39","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","volume":"127","author":"F Nadeu","year":"2016","unstructured":"Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, Jares P, Navarro A, Mart\u00edn-Garc\u00eda D, Be\u00e0 S, Salaverria I, Oldreive C, Aymerich M, Su\u00e1rez-Cisneros H, Rozman M, Villamor N, Colomer D, L\u00f3pez-Guillermo A, Gonz\u00e1lez M, Alcoceba M, Terol MJ, Colado E, Puente XS, L\u00f3pez-Ot\u00edn C, Enjuanes A, Campo E (2016) Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood 127(17):2122\u20132130. https:\/\/doi.org\/10.1182\/blood-2015-07-659144","journal-title":"Blood"},{"issue":"16","key":"6499_CR40","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1182\/blood-2017-11-817296","volume":"131","author":"K Takahashi","year":"2018","unstructured":"Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Andrew Futreal P, Ferrajoli A (2018) Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with Lenalidomide. Blood 131(16):1820\u20131832. https:\/\/doi.org\/10.1182\/blood-2017-11-817296","journal-title":"Blood"},{"issue":"1","key":"6499_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/bjh.15498","volume":"183","author":"C Vetro","year":"2018","unstructured":"Vetro C, Haferlach T, Jeromin S, Stengel A, Zenger M, Nadarajah N, Baer C, Weissmann S, Kern W, Meggendorfer M, Haferlach C (2018) Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses. Br J Haematol 183(1):47\u201359. https:\/\/doi.org\/10.1111\/bjh.15498","journal-title":"Br J Haematol"},{"issue":"2","key":"6499_CR42","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2018.195032","volume":"104","author":"P Baliakas","year":"2019","unstructured":"Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S, Agathangelidis A, Mattsson M, Sutton L-A, Minga E, Scarfo L, Rossi D, Davis Z, Villamor N, Parker H, Kotaskova J, Stalika E, Plevova K, Mansouri L, Cortese D, Navarro A, Delgado J, Larrayoz M, Young E, Anagnostopoulos A, Smedby KE, Juliusson G, Sheehy O, Catherwood M, Strefford JC, Stavroyianni N, Belessi C, Pospisilova S, Oscier D, Gaidano G, Campo E, Haferlach C, Ghia P, Rosenquist R, Stamatopoulos K, European Res Initiative CE (2019) Tailored approaches grounded on Immunogenetic features for refined prognostication in chronic lymphocytic leukemia. Haematologica 104(2):360\u2013369. https:\/\/doi.org\/10.3324\/haematol.2018.195032","journal-title":"Haematologica"},{"key":"6499_CR43","doi-asserted-by":"publisher","unstructured":"Miao Y, Zou YX, Gu DL, Zhu HC, Zhu HY, Wang L, Liang JH, Xia Y, Wu JZ, Shao CL, Fan L, Zhang Z, Xu W, Li JY (2019) SF3B1 mutation predicts unfavorable treatment-free survival in Chinese chronic lymphocytic leukemia patients. Ann Transl Med 7(8). https:\/\/doi.org\/10.21037\/atm.2019.03.63","DOI":"10.21037\/atm.2019.03.63"},{"issue":"6","key":"6499_CR44","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1158\/1078-0432.Ccr-18-4158","volume":"26","author":"C Brieghel","year":"2020","unstructured":"Brieghel C, da Cunha-Bang C, Yde CW, Schmidt AY, Kinalis S, Nadeu F, Andersen MA, Jacobsen LO, Andersen MK, Pedersen LB, Delgado J, Baumann T, Mattsson M, Mansouri L, Rosenquist R, Campo E, Nielsen FC, Niemann CU (2020) The number of signaling pathways altered by driver mutations in chronic lymphocytic leukemia impacts disease outcome. Clin Cancer Res 26(6):1507\u20131515. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-4158","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6499_CR45","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/cam4.2788","volume":"9","author":"K Shi","year":"2020","unstructured":"Shi K, Sun Q, Qiao C, Zhu H, Wang L, Wu J, Wang L, Fu J, Young KH, Fan L, Xia Y, Xu W, Li J (2020) 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia. Cancer Med 9(3):999\u20131007. https:\/\/doi.org\/10.1002\/cam4.2788","journal-title":"Cancer Med"},{"issue":"10","key":"6499_CR46","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.3324\/haematol.2019.229161","volume":"105","author":"E Tausch","year":"2020","unstructured":"Tausch E, Beck P, Schlenk RF, Jebaraj BJ, Dolnik A, Yosifov DY, Hillmen P, Offner F, Janssens A, Babu GK et al (2020) Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. Haematologica 105(10):2440\u20132447. https:\/\/doi.org\/10.3324\/haematol.2019.229161","journal-title":"Haematologica"},{"issue":"26","key":"6499_CR47","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1182\/blood.2019004492","volume":"135","author":"E Tausch","year":"2020","unstructured":"Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J, Bahlo J, Al-Sawaf O, Ritgen M, Fink AM, Eichhorst B, Kreuzer KA, Tandon M, Humphrey K, Jiang Y, Schary W, Bullinger L, Mertens D, Lur\u00e0 MP, Kneba M, D\u00f6hner H, Fischer K, Hallek M, Stilgenbauer S (2020) Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood 135(26):2402\u20132412. https:\/\/doi.org\/10.1182\/blood.2019004492","journal-title":"Blood"},{"key":"6499_CR48","doi-asserted-by":"publisher","unstructured":"Baldoni S, Del Papa B, De Falco F, Dorillo E, Sorrentino C, Rompietti C, Adamo FM, Nogarotto M, Cecchini D, Mondani E, Silva Barcelos EC, Moretti L, Mameli MG, Fabi B, Sorcini D, Stella A, Giancola R, Guardalupi F, Ulbar F, Plebani S, Guarente V, Rosati E, Di Nicola M, Marchioni M, Di Ianni M, Sportoletti P (2021) NOTCH1 activation negatively impacts on chronic lymphocytic leukemia outcome and is not correlated to the NOTCH1 and IGHV mutational status. Front Oncol 11. https:\/\/doi.org\/10.3389\/fonc.2021.668573","DOI":"10.3389\/fonc.2021.668573"},{"key":"6499_CR49","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.2147\/CMAR.S302245","volume":"13","author":"K Sk\u00f3rka","year":"2021","unstructured":"Sk\u00f3rka K, Chojnacki M, Masternak M, Karczmarczyk A, Subocz E, Wawrzyniak E, Giannopoulos K (2021) The predominant prognostic significance of notch1 mutation defined by emulsion Pcr in chronic lymphocytic leukemia. Cancer Manage Res 13:3663\u20133674. https:\/\/doi.org\/10.2147\/CMAR.S302245","journal-title":"Cancer Manage Res"},{"key":"6499_CR50","doi-asserted-by":"publisher","unstructured":"Jelloul FZ, Yang R, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda W, Jain N, Thompson P, Luthra R, Medeiros LJ, Patel KP (2022) Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res 116. https:\/\/doi.org\/10.1016\/j.leukres.2022.106827","DOI":"10.1016\/j.leukres.2022.106827"},{"issue":"3","key":"6499_CR51","doi-asserted-by":"publisher","first-page":"E100","DOI":"10.1002\/ajh.26457","volume":"97","author":"FZ Jelloul","year":"2022","unstructured":"Jelloul FZ, Yang RK, Wang P, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda WG, Jain N, Thompson PA, Luthra R, Medeiros LJ, Patel KP (2022) Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol 97(3):E100\u2013E102. https:\/\/doi.org\/10.1002\/ajh.26457","journal-title":"Am J Hematol"},{"key":"6499_CR52","doi-asserted-by":"publisher","unstructured":"Ahn A, Kim HS, Kim TY, Lee JM, Kang D, Yu H, Lee CY, Kim Y, Eom KS, Kim M (2023) Genetic and clinical characteristics of Korean chronic lymphocytic leukemia patients with high frequencies of MYD88 mutations. Int J Mol Sci 24(4). https:\/\/doi.org\/10.3390\/ijms24043177","DOI":"10.3390\/ijms24043177"},{"key":"6499_CR53","doi-asserted-by":"publisher","unstructured":"Aptullahoglu E, Wallis JP, Marr H, Marshall S, Bown N, Willmore E, Lunec J (2023) SF3B1 mutations are associated with resistance to Non-Genotoxic MDM2 Inhibition in chronic lymphocytic leukemia. Int J Mol Sci 24(14). https:\/\/doi.org\/10.3390\/ijms241411335","DOI":"10.3390\/ijms241411335"},{"issue":"2","key":"6499_CR54","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41375-022-01802-y","volume":"37","author":"L Mansouri","year":"2023","unstructured":"Mansouri L, Thorvaldsdottir B, Sutton LA, Karakatsoulis G, Meggendorfer M, Parker H, Nadeu F, Brieghel C, Laidou S, Moia R, Rossi D, Catherwood M, Kotaskova J, Delgado J, Rodr\u00edguez-Vicente AE, Benito R, Rigolin GM, Bonfiglio S, Scarfo L, Mattsson M, Davis Z, Gogia A, Rani L, Baliakas P, Foroughi-Asl H, Jylh\u00e4 C, Skaftason A, Rapado I, Miras F, Martinez-Lopez J, de la Serna J, Rivas JMH, Thornton P, Larr\u00e1yoz MJ, Calasanz MJ, F\u00e9s\u00fcs V, M\u00e1trai Z, B\u00f6d\u00f6r C, Smedby KE, Espinet B, Puiggros A, Gupta R, Bullinger L, Bosch F, Taz\u00f3n-Vega B, Baran-Marszak F, Oscier D, Nguyen-Khac F, Zenz T, Terol MJ, Cuneo A, Hern\u00e1ndez-S\u00e1nchez M, Pospisilova S, Mills K, Gaidano G, Niemann CU, Campo E, Strefford JC, Ghia P, Stamatopoulos K, Rosenquist R (2023) Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. Leukemia 37(2):339\u2013347. https:\/\/doi.org\/10.1038\/s41375-022-01802-y","journal-title":"Leukemia"},{"issue":"2","key":"6499_CR55","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/bjh.19459","volume":"205","author":"F Nguyen-Khac","year":"2024","unstructured":"Nguyen-Khac F, Baron M, Gui\u00e8ze R, Feugier P, Fayault A, Raynaud S, Troussard X, Droin N, Damm F, Smagghe L et al (2024) Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: focus on IGHV-mutated subgroups (a FILO study). Br J Haematol 205(2):495\u2013502. https:\/\/doi.org\/10.1111\/bjh.19459","journal-title":"Br J Haematol"},{"issue":"5","key":"6499_CR56","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3324\/haematol.2012.069369","volume":"98","author":"R Foa","year":"2013","unstructured":"Foa R, Del Giudice I, Guarini A, Rossi D, Gaidano G (2013) Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica 98(5):675\u2013685. https:\/\/doi.org\/10.3324\/haematol.2012.069369","journal-title":"Haematologica"},{"issue":"3","key":"6499_CR57","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00277-023-05554-2","volume":"103","author":"C-Y Shang","year":"2024","unstructured":"Shang C-Y, Bei L-Y, Wu J-Z, Sheng H-R, Yin H, Liang J-H, Wang L, Li J-Y, Li Y, Xu W (2024) NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia. Ann Hematol 103(3):1011\u20131012. https:\/\/doi.org\/10.1007\/s00277-023-05554-2","journal-title":"Ann Hematol"},{"issue":"2","key":"6499_CR58","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1182\/blood-2011-09-379966","volume":"119","author":"D Rossi","year":"2012","unstructured":"Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, Marasca R, Laurenti L, Bruscaggin A, Cerri M, Monti S, Cresta S, Fam\u00e0 R, De Paoli L, Bulian P, Gattei V, Guarini A, Deaglio S, Capello D, Rabadan R, Pasqualucci L, Dalla-Favera R, Fo\u00e0 R, Gaidano G (2012) Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 119(2):521\u2013529. https:\/\/doi.org\/10.1182\/blood-2011-09-379966","journal-title":"Blood"},{"issue":"16","key":"6499_CR59","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1182\/blood-2012-11-469627","volume":"121","author":"P Dreger","year":"2013","unstructured":"Dreger P, Schnaiter A, Zenz T, B\u00f6ttcher S, Rossi M, Paschka P, B\u00fchler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, D\u00f6hner H, Stilgenbauer S (2013) TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood 121(16):3284\u20133288. https:\/\/doi.org\/10.1182\/blood-2012-11-469627","journal-title":"Blood"},{"issue":"5","key":"6499_CR60","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/bjh.15877","volume":"185","author":"B Hu","year":"2019","unstructured":"Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG (2019) Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852\u2013864. https:\/\/doi.org\/10.1111\/bjh.15877","journal-title":"Br J Haematol"},{"key":"6499_CR61","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3389\/fimmu.2018.00633","volume":"9","author":"E Piovan","year":"2018","unstructured":"Piovan E, Tosello V, Amadori A, Zanovello P (2018) Chemotactic cues for NOTCH1-Dependent leukemia. Front Immunol 9:633. https:\/\/doi.org\/10.3389\/fimmu.2018.00633","journal-title":"Front Immunol"},{"issue":"7","key":"6499_CR62","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20110921","volume":"208","author":"G Fabbri","year":"2011","unstructured":"Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J, Grunn A, Fangazio M, Capello D, Monti S, Cresta S, Gargiulo E, Forconi F, Guarini A, Arcaini L, Paulli M, Laurenti L, Larocca LM, Marasca R, Gattei V, Oscier D, Bertoni F, Mullighan CG, Foa R, Pasqualucci L, Rabadan R, Dalla-Favera R, Gaidano G (2011) Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 208(7):1389\u20131401. https:\/\/doi.org\/10.1084\/jem.20110921","journal-title":"J Exp Med"},{"issue":"4","key":"6499_CR63","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/bjh.19604","volume":"205","author":"MY Gao","year":"2024","unstructured":"Gao MY, Georgiou A, Lin VS, Jahja M, White CA, Anderson MA, McCormack MP, Roberts AW, Huang DCS, Thijssen R (2024) Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic leukaemia: in vitro insights and clinical implications. Br J Haematol 205(4):1389\u20131394. https:\/\/doi.org\/10.1111\/bjh.19604","journal-title":"Br J Haematol"},{"key":"6499_CR64","doi-asserted-by":"publisher","first-page":"104711","DOI":"10.1016\/j.exphem.2025.104711","volume":"143","author":"X Li","year":"2025","unstructured":"Li X, Wang J, Hu L, Cheng T (2025) How age affects human hematopoietic stem and progenitor cells and the strategies to mitigate aging. Exp Hematol 143:104711. https:\/\/doi.org\/10.1016\/j.exphem.2025.104711","journal-title":"Exp Hematol"},{"issue":"2","key":"6499_CR65","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1182\/blood-2012-09-399725","volume":"121","author":"M Cazzola","year":"2013","unstructured":"Cazzola M, Rossi M, Malcovati L, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie M (2013) Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood 121(2):260\u2013269. https:\/\/doi.org\/10.1182\/blood-2012-09-399725","journal-title":"Blood"},{"issue":"12","key":"6499_CR66","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.3324\/haematol.2020.261891","volume":"106","author":"F Pozzo","year":"2021","unstructured":"Pozzo F, Bittolo T, Tissino E, Vit F, Vendramini E, Laurenti L, D\u2019Arena G, Olivieri J, Pozzato G, Zaja F, Chiarenza A, Di Raimondo F, Zucchetto A, Bomben R, Rossi FM, Del Poeta G, Dal Bo M, Gattei V (2021) SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. Haematologica 106(12):3125\u20133135. https:\/\/doi.org\/10.3324\/haematol.2020.261891","journal-title":"Haematologica"},{"issue":"4","key":"6499_CR67","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1080\/10428194.2024.2441858","volume":"66","author":"V Guglielmana","year":"2025","unstructured":"Guglielmana V, Rossi D (2025) Prognostic and predictive impact of NOTCH1 mutation in chronic lymphocytic leukemia: a systematic review. Leuk Lymphoma 66(4):584\u2013593. https:\/\/doi.org\/10.1080\/10428194.2024.2441858","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"6499_CR68","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC (2018) Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 379(26):2517\u20132528. https:\/\/doi.org\/10.1056\/NEJMoa1812836","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06499-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06499-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06499-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:58:00Z","timestamp":1764226680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06499-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":68,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6499"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06499-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study does not require ethical approval or patient consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not commissioned; externally peer reviewed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Provenance and peer review"}},{"value":"The funding body had no role in the design of the study, collection, analysis, interpretation of data, or writing of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Diclaimer"}}]}}